PMID- 37246240
OWN - NLM
STAT- MEDLINE
DCOM- 20231107
LR  - 20231107
IS  - 1365-2885 (Electronic)
IS  - 0140-7783 (Linking)
VI  - 46
IP  - 6
DP  - 2023 Nov
TI  - Pharmacokinetics of robenacoxib following single intravenous, subcutaneous and 
      oral administrations in Baladi goats (Capra hircus).
PG  - 385-392
LID - 10.1111/jvp.13396 [doi]
AB  - The purpose of this study was to assess the pharmacokinetics of robenacoxib (RX), 
      a COX-2 selective non-steroidal anti-inflammatory drug, in goats after single 
      intravenous (IV), subcutaneous (SC) and oral (PO) administrations. 5-month-old 
      healthy female goats (n = 8) were used. The animals were subjected to a 
      three-phase, two-dose (2 mg/kg IV, 4 mg/kg SC, PO) unblinded, parallel study 
      design, with a four-month washout period between the IV and SC treatment, and a 
      one-week period between the SC and PO treatment. Blood was drawn from the jugular 
      vein in heparinized vacutainer tubes at 0, 0.085 (for IV only), 0.25, 0.5, 0.75, 
      1, 1.5, 2, 4, 6, 8, 10 and 24 h. Plasma RX concentrations were measured using 
      HPLC coupled to a UV multiple wavelength detector, and the data were 
      pharmacokinetically analysed using ThothPro 4.3 software in a non-compartmental 
      approach. Following IV administration, terminal elimination half-life, volume of 
      distribution and total clearance were 0.32 h, 0.24 L/kg and 0.52 L/h/kg, 
      respectively. For SC and PO, the mean peak plasma concentrations were 2.34 and 
      3.34 mug/mL at 1.50 and 0.50 h, respectively. The t1/2lambdaz was significantly 
      different between the IV and the extravascular (EV) administrations (0.32 h IV vs 
      1.37 h SC and 1.63 h PO), suggesting the occurrence of a flip-flop phenomenon. 
      The significant difference in V(d) values between IV (0.24 L/kg) and EV 
      (0.95 L/kg SC and 1.71 L/kg; corrected for F %) routes might have also triggered 
      the t1/2lambdaz difference. The absolute average SC and PO bioavailability were high 
      (98% and 91%, respectively). In conclusion, the IV administration of RX might not 
      be suitable for goats, due to its short t1/2lambdaz. The EV routes, however, appear to 
      be convenient for the drug's occasional use.
CI  - (c) 2023 The Authors. Journal of Veterinary Pharmacology and Therapeutics published 
      by John Wiley & Sons Ltd.
FAU - Fadel, Charbel
AU  - Fadel C
AUID- ORCID: 0000-0001-9996-5942
AD  - Department of Veterinary Medicine, University of Sassari, Sassari, Italy.
FAU - Lebkowska-Wieruszewska, Beata
AU  - Lebkowska-Wieruszewska B
AUID- ORCID: 0000-0002-1569-0599
AD  - Department of Pharmacology, Toxicology and Environmental Protection, University 
      of Life Sciences, Lublin, Poland.
FAU - Zizzadoro, Claudia
AU  - Zizzadoro C
AUID- ORCID: 0000-0003-4837-7491
AD  - Department of Veterinary Medicine, University of Bari, Valenzano (Bari), Italy.
FAU - Lisowski, Andrzej
AU  - Lisowski A
AUID- ORCID: 0000-0003-1463-9908
AD  - Institute of Animal Breeding and Biodiversity Conservation, University of Life 
      Sciences, Lublin, Poland.
FAU - Poapolathep, Amnart
AU  - Poapolathep A
AUID- ORCID: 0000-0001-5322-3281
AD  - Faculty of Veterinary Medicine, Department of Pharmacology, Kasetsart University, 
      Bangkok, Thailand.
FAU - Giorgi, Mario
AU  - Giorgi M
AUID- ORCID: 0000-0003-3657-4703
AD  - Department of Veterinary Medicine, University of Sassari, Sassari, Italy.
AD  - Department of Veterinary Sciences, University of Pisa, Pisa, Italy.
LA  - eng
GR  - Universita di Pisa/
PT  - Journal Article
DEP - 20230528
PL  - England
TA  - J Vet Pharmacol Ther
JT  - Journal of veterinary pharmacology and therapeutics
JID - 7910920
RN  - Z588009C7C (robenacoxib)
SB  - IM
MH  - Female
MH  - Animals
MH  - *Goats
MH  - Area Under Curve
MH  - Injections, Subcutaneous/veterinary
MH  - Administration, Oral
OTO - NOTNLM
OT  - coxibs
OT  - goats
OT  - non-steroidal anti-inflammatory drugs
OT  - pain management
OT  - pharmacokinetics
OT  - robenacoxib
EDAT- 2023/05/29 00:42
MHDA- 2023/11/07 06:45
CRDT- 2023/05/28 23:33
PHST- 2023/04/19 00:00 [revised]
PHST- 2023/03/23 00:00 [received]
PHST- 2023/05/02 00:00 [accepted]
PHST- 2023/11/07 06:45 [medline]
PHST- 2023/05/29 00:42 [pubmed]
PHST- 2023/05/28 23:33 [entrez]
AID - 10.1111/jvp.13396 [doi]
PST - ppublish
SO  - J Vet Pharmacol Ther. 2023 Nov;46(6):385-392. doi: 10.1111/jvp.13396. Epub 2023 
      May 28.